GlaxoSmithKline said U.S. regulators had approved its ovarian cancer treatment Zejula for wider use in some advanced cancers, in a boost to the British drugmaker's oncology portfolio as it competes with rival AstraZeneca.

from Reuters: Company News https://ift.tt/2paFXp7
via IFTTT
from Reuters: Company News https://ift.tt/2paFXp7
via IFTTT
Post a Comment